GeneDx (WGS) CEO sells 10,501 shares to cover taxes
GeneDx Holdings Corp. CEO Katherine Stueland exercised 18,750 Restricted Stock Units (RSUs) and subsequently sold 10,501 shares of Class A Common Stock. These sales were conducted as a "sell to cover" transaction to satisfy tax withholding obligations related to the RSU vesting and were not a discretionary sale. Following these transactions, Ms. Stueland retained a significant equity position in the company, including common stock, outstanding RSUs, and stock options.
Tax-driven stock sale by GeneDx (WGS) CFO after RSU vesting
GeneDx Holdings Corp. (WGS) CFO Kevin Feeley exercised 7,197 Restricted Stock Units and subsequently sold 3,728 shares. This sale was explicitly stated to be for covering tax withholding obligations associated with the RSU vesting and was not a discretionary transaction. After these transactions, Feeley beneficially owns 44,945 Class A Common shares, along with unvested RSUs for 71,667 shares and options for 25,906 shares.
GeneDx Holdings (WGS) director receives 1,146 shares at no cash cost
GeneDx Holdings Corp. director Thomas Fuchs received 1,146 shares of Class A Common Stock from the settlement of Restricted Stock Units (RSUs) on September 17, 2026, at no cash cost. After this transaction, Fuchs directly holds 1,146 common shares and 2,292 RSUs. The RSUs are set to vest in three equal installments through September 2028, contingent on his continued service.
GeneDx CEO Katherine Stueland sells $1.03m in stock
GeneDx CEO Katherine Stueland sold 10,501 shares of the company’s Class A Common Stock for over $1 million to cover tax obligations from vested restricted stock units (RSUs). These transactions occurred on September 16, 2026, amid a 23% surge in WGS stock, though InvestingPro analysis suggests the stock is currently overvalued. Stueland also acquired 18,750 shares through RSU settlements on the same date.
GeneDx Director Thomas Fuchs Reports RSU Conversion to 1,146 Shares
Thomas Fuchs, a director at GeneDx Holdings Corp. (NASDAQ:WGS), converted 1,146 restricted stock units (RSUs) into Class A Common Stock shares on September 17, 2026. This transaction represents the first installment of a three-part vesting schedule, with 2,292 RSUs remaining. The RSUs vest in equal parts on September 17 of 2026, 2027, and 2028, contingent on Fuchs's continued service.
GeneDx (WGS) CFO sells stock for taxes, holds 41,476 shares
GeneDx CFO Kevin Feeley sold 1,285 shares of Class A Common Stock for $84.2179 per share to cover tax withholding obligations from vested Restricted Stock Units. This transaction, which was not discretionary, occurred on September 9, 2026, after 2,462 RSUs settled into shares. Following the sale, Feeley beneficially owns 41,476 shares of Class A Common Stock, with additional RSUs and options vesting over time.
GeneDx (WGS) CEO sells shares in tax-withholding trade
GeneDx Holdings Corp. CEO Katherine Stueland sold 3,692 shares of Class A Common Stock at a weighted average price of $84.22 per share. This sale was a "sell to cover" transaction to satisfy tax withholding obligations related to the vesting of 6,547 Restricted Stock Units (RSUs) on September 9, 2026, and was not a discretionary sale. Following the transaction, Ms. Stueland beneficially owns 107,227 shares of Class A Common Stock, along with significant outstanding RSUs and stock options.
GeneDx Holdings (WGS) CFO sells shares in tax-cover trade
GeneDx Holdings (WGS) CFO Kevin Feeley sold 372 shares of Class A Common Stock at a weighted average price of $83.839 per share. This sale was a non-discretionary "sell to cover" transaction to satisfy tax withholding obligations after 717 Restricted Stock Units (RSUs) vested on September 1, 2026. Following the transaction, Feeley beneficially owned 40,299 shares of Class A Common Stock, along with contingent rights to 81,326 additional RSU shares and options for 25,906 shares.
GeneDx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against GeneDx Holdings Corp. - WGS
ClaimsFiler is reminding investors who lost over $100,000 in GeneDx Holdings Corp. (NasdaqGS: WGS) to file lead plaintiff applications by August 3, 2026, in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives failed to disclose material information between April 16, 2025, and May 4, 2026, leading to a significant stock price drop after the company reported lower-than-expected financial results and an impairment loss. Investors can visit ClaimsFiler.com or contact Kahn Swick & Foti, LLC for more information and legal options.
GeneDx Stock Stumbles As Momentum Turns Against It
GeneDx Holdings (WGS) stock is currently experiencing a downturn due to softer Q3 revenue outlook, technical sell signals, and profit-taking. Despite rapid growth in test volumes and genomic revenues suggesting long-term potential, the company faces challenges with cash burn and weak reimbursement collections, raising concerns about future funding needs. The article also highlights strong gross margins but warns about rising costs for genome tests impacting profitability.
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by GeneDx Holdings Corp. (NASDAQ: WGS). The firm encourages investors who purchased GeneDx securities before April 16, 2025, and still hold them, to contact them to assist in the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - HBSS
GeneDx Holdings (NASDAQ: WGS) is facing a securities class action lawsuit following a significant 49% stock drop and a 94% write-off related to its Fabric Genomics acquisition. The lawsuit alleges that GeneDx made misleading statements about the acquisition's importance, its margins, and its average reimbursement rates. Investors who purchased shares between April 16, 2025, and May 4, 2026, and suffered losses are urged to contact Hagens Berman.
GeneDx Holdings Corp. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - WGS
The DJS Law Group has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for alleged securities law violations between April 16, 2025, and May 4, 2026. The lawsuit claims GeneDx made false and misleading statements, leading to a drop in adjusted gross margin in Q1 2026 and lowered full-year earnings projections. Shareholders who suffered losses during this period are encouraged to contact the firm to discuss their rights and potential lead plaintiff appointments.
GeneDx Holdings Corp. - Class A Common Stock (NQ: WGS
This page provides a compilation of recent news headlines regarding GeneDx Holdings Corp. (WGS). It covers earnings reports, insider transactions, stock performance, and analyst commentary related to the company's genomic testing and AI-driven healthcare insights. The articles span from early 2026 to August 2026, highlighting significant events such as Q2 2026 earnings beats and notable insider activity.
Is GeneDx’s Direct-to-Family Exome Platform Reshaping The Investment Case For GeneDx Holdings (WGS)?
GeneDx Holdings (WGS) has launched a direct-to-family, clinician-guided exome testing platform, aiming to expand access for pediatric patients with developmental delays, intellectual disabilities, or epilepsy. This initiative aligns with updated American Academy of Pediatrics guidance supporting exome sequencing as a first-tier test and could boost GeneDx's market in pediatric genomics. However, the investment case remains subject to reimbursement pressures and whether payers will consistently support broad exome use.
GeneDx Holdings (WGS), Why Is This Fresh Development Drawing Attention?
GeneDx Holdings (WGS) has launched an online exome testing pathway, allowing U.S. families to directly initiate clinician-guided genetic tests for children with developmental conditions. This development comes as the stock shows strong recent momentum, despite significant year-to-date and one-year declines. While one valuation model suggests the stock is slightly overvalued, another (Simply Wall St's DCF) indicates deep undervaluation, highlighting mixed sentiment and the importance of examining underlying data.
WGS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Faruqi & Faruqi, LLP is investigating potential claims against GeneDx Holdings Corp. (NASDAQ: WGS) and reminds investors of the August 3, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the importance of Fabric Genomics, the durability of reimbursement rates, and the company's gross margins. This follows a significant drop in share price after GeneDx disclosed missed Q1 financial results and cut 2026 guidance, revealing a goodwill impairment charge related to the Fabric Genomics acquisition.
GeneDx Holdings Corp. (NASDAQ:WGS) Analysts Are Pretty Bullish On The Stock After Recent Results
Analysts are showing increased optimism for GeneDx Holdings Corp. (NASDAQ:WGS) after its latest second-quarter results, which saw revenues beat expectations and statutory losses narrow more than anticipated. Although revenue forecasts remain unchanged for the coming year, analysts have revised their loss per share predictions, leading to a 5.0% increase in the consensus price target to US$85.89. The company's revenue growth is projected to outpace the industry average, despite a slowdown compared to its historical performance.
GeneDx (WGS) Stock Climbs On Strong Margins As Reimbursement Lags
GeneDx Holdings Corp. (WGS) saw its stock climb 4.8% after reporting strong Q2 2026 results, with exome and genome revenue reaching US$100.3 million and a gross margin of around 70%. The company achieved adjusted profitability ahead of schedule, demonstrating its core engine's efficiency. However, reimbursement challenges persist, with blended average reimbursement per test remaining flat and outpatient genome collection below industry targets, raising concerns about the durability of its profit profile.
[10-Q] GeneDx Holdings Corp. Quarterly Earnings Report
GeneDx Holdings Corp. (WGS) filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The report details a new financing structure involving an amended loan agreement for an additional $50 million, increasing debt capacity to $150 million, and a conditional share issuance of approximately $5 million to Blackstone affiliates, which could dilute existing shareholders. The company reported a net loss of $17.7 million for Q2 2026 and $81.1 million for the six months ended June 30, 2026, and also recorded a $31.3 million impairment loss related to the Fabric Genomics acquisition.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Faruqi & Faruqi, LLP reminds investors of the August 3, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the importance of Fabric Genomics, its margins, and reimbursement rates, leading to significant stock price drops. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the law firm.
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) for alleged securities fraud. The lawsuit claims GeneDx made misleading statements, revealed a drop in adjusted gross margin, lowered projected earnings, and announced a significant impairment, causing investor damages. Shareholders who purchased WGS shares during the class period (April 16, 2025, to May 4, 2026) are encouraged to contact SBS to discuss potential lead plaintiff appointments before the August 3, 2026 deadline.
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS) on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made materially false and misleading statements regarding the importance of Fabric Genomics, its declining margins, and non-durable reimbursement rates. Investors who suffered losses are encouraged to contact the firm to explore their options, with a lead plaintiff deadline of August 3, 2026.
WGS Deadline: WGS Investors with Losses in Excess of $100K Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased common stock of GeneDx Holdings Corp. (NASDAQ: WGS) between April 16, 2025, and May 4, 2026, of the August 3, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that GeneDx made misleading statements regarding the positive impact of its Fabric acquisition on the company's financials and operations, when in reality, significant problems existed that negatively impacted the business. Investors with losses exceeding $100,000 are encouraged to join the class action to seek compensation.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has reminded investors of GeneDx Holdings Corp. (NASDAQ: WGS) with substantial losses that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives failed to disclose material information, leading to a 49.2% stock decline after the company reported a drop in adjusted gross margin, missed revenue estimates, lowered full-year guidance, and disclosed a $31.2 million impairment loss related to its acquisition of Fabric Genomics. Investors who purchased shares between April 16, 2025, and May 4, 2026, are encouraged to contact KSF to discuss their legal rights.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has reminded investors of GeneDx Holdings Corp. (NASDAQ: WGS) with substantial losses that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives failed to disclose material information during the Class Period, leading to a significant drop in stock price after the company reported lower-than-expected financial results and an impairment loss related to its Fabric Genomics acquisition. Investors who purchased shares between April 16, 2025, and May 4, 2026, are encouraged to contact KSF for legal counsel.
GeneDx Holdings Corp. 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against GeneDx Holdings Corp. - WGS
Kahn Swick & Foti, LLC (KSF) is reminding investors in GeneDx Holdings Corp. (NasdaqGS: WGS) that they have until August 3, 2026, to apply for lead plaintiff in a securities class action lawsuit. The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the company's financial performance, including deteriorating adjusted gross margins and missed revenue estimates. These alleged misrepresentations led to a significant drop in GeneDx's stock price.
GENEDX HOLDINGS DEADLINE MONDAY AUGUST 3rd: Bragar Eagel & Squire, P.C. Urges GeneDx Holdings Corp. Investors to Contact the Firm Regarding Lead Plaintiff Deadline
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GeneDx Holdings Corp. (NASDAQ:WGS) for alleged federal securities law violations. The lawsuit claims GeneDx made false and misleading statements about its business, leading to a significant drop in stock price after the company reported poor financial results and lowered revenue guidance. Investors who purchased WGS common stock between April 16, 2025, and May 4, 2026, have until August 3, 2026, to apply to be lead plaintiff.
HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), urging investors with substantial losses to contact the firm. The lawsuit alleges that GeneDx and its executives misled investors regarding the benefits of acquiring Fabric Genomics, concealing integration problems that severely harmed the company's business. Following corrective disclosures on May 4, 2026, GeneDx's stock plummeted by 49.2%, resulting in significant shareholder value destruction.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC is reminding investors that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. The lawsuit alleges that GeneDx and its executives failed to disclose material information, leading to a 49.2% stock decline after the company reported disappointing Q1 2026 financial results and an impairment loss related to its acquisition of Fabric Genomics. Investors who purchased GeneDx shares between April 16, 2025, and May 4, 2026, are encouraged to contact KSF for more information.
MONDAY DEADLINE: GeneDx Holdings Corp. (WGS) Investors with
Robbins Geller Rudman & Dowd LLP announced a Monday, August 3, 2026 deadline for investors who purchased GeneDx Holdings Corp. (WGS) common stock between April 16, 2025, and May 4, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that GeneDx made false or misleading statements regarding the viability of its acquisition, Fabric Genomics, which led to a significant stock drop after the company revealed an impairment loss and reduced earnings projections. Investors who suffered substantial losses are encouraged to contact the firm to lead the class action.
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has reminded investors of GeneDx Holdings Corp. that they have until August 3, 2026, to file lead plaintiff applications in a securities class action lawsuit. This action alleges that GeneDx and its executives made material misrepresentations regarding the company's performance, particularly concerning the Fabric Genomics acquisition, which led to a 49.2% stock decline after the company disclosed disappointing Q1 2026 financial results and lowered guidance. Investors who purchased shares between April 16, 2025, and May 4, 2026, and incurred substantial losses, are encouraged to contact KSF for legal guidance.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
SueWallSt is alerting investors of GeneDx Holdings Corp. (NASDAQ: WGS) about a pending securities class action lawsuit, with a lead plaintiff deadline of August 3, 2026. The lawsuit stems from the unraveling of GeneDx's acquisition of Fabric Genomics, which was initially touted as a growth catalyst but resulted in a $31.2 million impairment charge and a significant stock price drop. Shareholders who purchased WGS shares between April 16, 2025, and May 4, 2026, may be eligible to recover losses due to alleged misleading statements regarding the acquisition's potential.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 3, 2026 in GeneDx Holdings Corp. Lawsuit - WGS
SueWallSt is alerting investors in GeneDx Holdings Corp. (WGS) about a pending securities class action lawsuit, with a lead plaintiff deadline of August 3, 2026. The lawsuit stems from the unraveling of WGS's acquisition of Fabric Genomics, which was initially promised as a growth catalyst but resulted in a $31.2 million impairment charge and a significant stock drop. The firm encourages shareholders who purchased WGS shares between April 16, 2025, and May 4, 2026, to contact them regarding potential recovery of losses.
MONDAY DEADLINE: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - WGS
Robbins Geller Rudman & Dowd LLP announces a lead plaintiff deadline of Monday, August 3, 2026, for investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made false or misleading statements regarding the viability of Fabric Genomics, an AI-driven genomic interpretation firm it acquired, leading to a significant stock drop. Investors with substantial losses have the opportunity to seek appointment as lead plaintiff in the class action.
Class Action Lawsuit Filed Against GeneDx Holdings Corp. (WGS) - Recover Losses - Contact Levi & Korsinsky Before August 3, 2026
A class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ:WGS) by Levi & Korsinsky, LLP, on behalf of investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx Holdings Corp. made false and misleading statements regarding the viability and financial benefits of its Fabric acquisition, leading to artificially inflated stock prices. Investors who suffered losses are encouraged to contact Levi & Korsinsky to explore potential recovery under federal securities laws before August 3, 2026.
Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 3, 2026 - WGS
Levi & Korsinsky, LLP has issued a reminder to investors in GeneDx Holdings Corp. (NASDAQ: WGS) about a pending securities class action lawsuit. The lawsuit alleges that GeneDx management misled investors about deteriorating reimbursement rates and margin compression between April 16, 2025, and May 4, 2026. Investors who suffered losses have until August 3, 2026, to apply for lead plaintiff appointment.
WGS DEADLINE ALERT: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- August 3, 2026 Deadline
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (WGS), alerting investors with substantial losses to an August 3, 2026 deadline to lead the class action. The lawsuit alleges that GeneDx misled investors about the benefits of its Fabric Genomics acquisition, concealing significant integration problems, which led to a substantial drop in share prices after corrective disclosures on May 4, 2026. Investors who purchased WGS common stock between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the firm.
WGS UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Faruqi & Faruqi, LLP is reminding investors of the August 3, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDx and its executives made misleading statements regarding the importance of Fabric Genomics, projected margins, and average reimbursement rates, which led to a significant drop in share price after the Q1 2026 financial results were announced. Investors who purchased GeneDx securities between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to contact the law firm.
Levi & Korsinsky Reminds GeneDx Holdings Corp. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 3, 2026 - WGS
Levi & Korsinsky, LLP is alerting investors of GeneDx Holdings Corp. (NASDAQ: WGS) about a pending securities class action lawsuit. The lawsuit alleges that GeneDx concealed deteriorating reimbursement rates and margin compression, leading to a significant drop in share value. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, and suffered losses may be eligible to join, with a lead plaintiff deadline of August 3, 2026.
Portnoy Law Firm Announces Class Action on Behalf of GeneDX Holdings, Corp. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of GeneDX Holdings, Corp. (NASDAQ: WGS) investors who purchased securities between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDX and its executives made misleading statements regarding the importance of Fabric Genomics, its reimbursement rates, and its financial prospects. This action follows a significant drop in GeneDX's share price after the company missed Q1 financial results and cut its 2026 guidance.
BlackRock (NYSE: BLK) discloses 5.5% beneficial ownership in GeneDx (WGS)
BlackRock, Inc. has filed a Schedule 13G disclosing a 5.5% beneficial ownership in GeneDx Holdings Corp. (WGS). The filing indicates BlackRock owns 1,622,518 shares of Class A stock, with sole voting power over 1,588,670 shares and sole dispositive power over all 1,622,518 shares. No single client of BlackRock holds more than five percent of GeneDx's outstanding common shares.
WGS 6-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), urging investors with substantial losses to contact the firm before the August 3, 2026, lead plaintiff deadline. The lawsuit alleges GeneDx misled investors about the benefits and integration of its Fabric Genomics acquisition, concealing significant problems that led to a substantial drop in stock value after corrective disclosures. Investors who purchased WGS stock between April 16, 2025, and May 4, 2026, and suffered losses are encouraged to participate.
Portnoy Law Firm Announces Class Action on Behalf of GeneDX Holdings, Corp. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in GeneDX Holdings, Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDX made false and misleading statements to investors between April 16, 2025, and May 4, 2026, regarding its business, including the importance of Fabric Genomics, its reimbursement rates, and gross margins. This announcement follows a significant share price drop after GeneDX missed Q1 financial targets and cut its 2026 guidance.
WGS Shareholders Have Opportunity to Lead GeneDx Holdings Corp. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC announces that a class action lawsuit has been filed against GeneDx Holdings Corp. (NASDAQ:WGS) for alleged violations of federal securities laws. The lawsuit covers investors who purchased GeneDx securities between April 16, 2025, and May 4, 2026, claiming the company made false and misleading statements regarding its business, operations, and prospects, specifically concerning Fabric Genomics, margins, and reimbursement rates. Investors who suffered losses have until August 3, 2026, to request to be appointed as lead plaintiff.
Portnoy Law Firm Announces Class Action on Behalf of GeneDX Holdings, Corp. Investors
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors of GeneDX Holdings, Corp. (NASDAQ: WGS). The lawsuit alleges that GeneDX made false and misleading statements regarding the importance of Fabric Genomics, its margins, and average reimbursement rates, leading to a significant drop in share price. Investors who purchased securities between April 16, 2025, and May 4, 2026, have until August 3, 2026, to file as a lead plaintiff.
GeneDx Holdings Corp. Class A Revenue Breakdown – BX:WGS
This article provides an overview of GeneDx Holdings Corp. Class A (BX:WGS) financial information available on TradingView, focusing on its revenue breakdown and segments. It highlights that market data is provided by ICE Data Services and FactSet, with SEC filings from Quartr. The content mainly navigates through various financial and community features offered by TradingView related to the company.
MONDAY DEADLINE: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead GeneDx Class Action Lawsuit - WGS
Investors in GeneDx Holdings Corp. (NASDAQ: WGS) who suffered losses between April 16, 2025, and May 4, 2026, have until August 3, 2026, to seek appointment as lead plaintiff in a class action lawsuit. The lawsuit alleges that GeneDx made misleading statements regarding the viability of its acquisition, Fabric Genomics, leading to a significant stock drop. Robbins Geller Rudman & Dowd LLP is representing the investors.
WGS 9-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ:
Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GeneDx Holdings Corp. (NASDAQ: WGS), urging investors with significant losses to come forward. The lawsuit alleges that GeneDx and its executives made false and misleading statements about the benefits of acquiring Fabric Genomics, concealing integration problems that led to missed revenue estimates, lowered guidance, and a $31.2 million impairment charge, causing a 49.2% stock plummet. The lead plaintiff deadline is August 3, 2026.
GENEDX HOLDINGS DEADLINE AUGUST 3rd: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against GeneDx Holdings Corp. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has announced a class action lawsuit filed against GeneDx Holdings Corp. (NASDAQ:WGS) on behalf of investors who purchased common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx and its executives made false and misleading statements regarding the company's business, particularly concerning Fabric Genomics, reimbursement rates, and gross margins. Investors are encouraged to contact the law firm by the August 3, 2026 deadline to apply for lead plaintiff in the case.
